Clinical observation of Ranibizumab on retinopathy of prematurity with or without preretinal hemorrhage

Abstract

AIM: To compare the therapeutic effect of Ranibizumab on retinopathy of prematurity(ROP)with or without preretinal hemorrhage(PRH). METHODS: From April 2017 to January 2018, a retrospective study was carried out on the diagnosed and treated ROP cases 66 eyes of 34 in the Affiliated Eye Hospital of Nanchang University. All the infants were divided into two groups according to PRH or not. All patients were treated with intravitreal Ranibizumab under tropical anesthesia. The infants were followed up, and the cure and retreatment rate between the two groups after initial treatment were compared. RESULTS: After the initial treatment of intravitreal Ranibizumab, the cure rate was 65%(17)and 98%(39), and the retreatment rate was 35%(9)and 2%(1)in bleeding and non-bleeding group, respectively. 9 eyes with PRH needed retreatment; however, only 1 eye retreatment in the non-bleeding group. Notably, all the retreatment cases were cured by once more intravitreal Ranibizumab. The cure rate between two groups was statistically significant. CONCLUSION: The curative effect with initial treatment of ROP with PRH was significantly lower than that without PRH. The retreatment cases were attenuated by repeated intravitreal Ranibizumab treatment.

Keywords

• retinopathy of prematurity
• preretinal hemorrhage
• ranibizumab
• intravitreal injection